Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses the challenges and advancements in treating acute myeloid leukemia (AML) in patients who are unfit for intensive chemotherapy. Dr Žučenka emphasizes the importance of personalized treatment approaches, considering factors such as age, comorbidities, and patient preferences. Dr Žučenka also highlights the role of low-intensity therapies, including hypomethylating agents and targeted therapies, in improving outcomes for these patients.